Female Sexual Dysfunction Treatment Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global market value of female sexual dysfunction treatment was valued at USD 435.2 million in 2022, and a CAGR of 11.3% is expected during the forecast period. Sexual dysfunction is a psychiatric disorder in which a female finds herself unable to enjoy physical intimacy. The increasing prevalence of chronic diseases is driving growth in the market. This factor has a significant impact on future market growth. The industry is about to expect healthy growth during the forecast period due to technological advancements. The increasing number of patients with diabetes and cardiovascular disease is driving the growth of the market significantly.

Impact of Covid-19

The impact of COVID-19 on the female sexual dysfunction treatment market has been mixed. The pandemic had led to disruptions in healthcare services, including reduced access to clinics and fewer in-person appointments, which had affected the diagnosis and treatment of female dysfunction. The increasing prevalence of stress and anxiety among patients is driving growth in the market. Increased focus on remote healthcare and telemedicine solutions has improved access to treatment for some individuals. The pandemic had heightened the issue of mental health awareness, which is often linked to sexual dysfunction, potentially leading to increased demand for treatment.

Growth Drivers

Increasing awareness about sexual health, advancements in medical technology, and an increasing number of chronic disease patients are driving growth in the market. Efforts to destigmatize seeking treatment are driving growth in the market significantly. The expansion of healthcare infrastructure and services is the real cause behind the growth in revenue in the market. Growing awareness campaigns and educational initiatives are driving the growth of the market.

The development of innovative treatment options such as novel pharmaceuticals, medical devices, and therapeutic approaches tailored to address female sexual dysfunction more effectively. Evolving societal attitudes and norms surrounding female sexuality and healthcare lead to a greater acceptance of discussing and seeking treatment for sexual dysfunction, reducing stigma, and encouraging women to seek help.

Growing investment by pharmaceutical companies, research institutions, and healthcare organizations in studying female sexual health and developing novel treatment modalities drives innovation and market expansion. The expansion of healthcare infrastructure, especially in emerging markets, improves access to healthcare services and facilitates the diagnosis and treatment of female sexual dysfunction. Rising incidences of gynecological conditions are driving the growth of the market. The surge in demand for treatment of such disorders in menopausal women is propelling the growth of the market.

The increasing prevalence of stress and anxiety among patients is driving growth in the market. Increased focus on remote healthcare and telemedicine solutions has improved access to treatment for some individuals. After the pandemic, the resurgence of female patients in hospitals is boosting market growth. The surge in incidences of other sexual disorders like hypoactive sexual desire disorder, genito-pelvic penetration pain disorder, and vaginismus is driving growth in the market. The high adoption of estrogen therapy among postmenopausal women is the key factor propelling the growth of the market.

Segmentation

By Route of Administration

·         Oral

·         Parenteral

·         Topical

By Distribution Channel

·         Hospital Pharmacies

·         Drug Pharmacies

·         Retail Pharmacies

·         Online Stores

Based on Disease

·         Hypoactive sexual desire disorder

·         Dyspareunia

·         Others

By Drug Analysis

·         Flibanserin

·         Bremelanotide

·         Ospemifane

·         Estrogen Therapy

·         Others

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Female Sexual Dysfunction Treatment Market Route of Administration Segmentation

On the basis of route of administration, the female dysfunction treatment market is segmented into oral, parenteral, and topical. Oral segmentation is witnessing significant growth during the forecast period. Pills such as Flibanserin and Bremalanotide are taken orally. Creams or gels containing hormones are applied directly to the genital area. Hormonal therapies, psychotherapy, and physical therapy are also in style. Pelvic floor exercise, or techniques to improve blood flow to the genital area.

Female Sexual Dysfunction Treatment Market Distribution Channel Segmentation

On the basis of distribution channel, the sexual dysfunction treatment market is segmented into hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacy is the leading segment because of the faith of most people in hospitals. Hospitals typically have specialized health care professionals, such as gynecologists and urologists. Hospital pharmacies often have a broad range of medications available. Patients do feel more comfortable discussing their issues, like sexual problems, with more convenience over there.

Certain treatments for female sexual dysfunction are covered by insurance plans when obtained through hospital pharmacies, making them more affordable and accessible for patients. Retail pharmacies are another segment due to easy accessibility and increasing growth in e-commerce, which has made online services more successful in recent times. In some cases, online mode is the best even for this disease, as by staying at home, you can order your desired products and easily and conveniently get the medicine.

Regional Outlook

On the basis of the regions, the market is segmented into 5 parts: Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Due to the rising adoption of therapies in the region, the North American market is expected to dominate the market during the forecast period significantly. The rising prevalence of chronic diseases in the region, along with increasing technological advancements, is driving the growth of the market. In the Latin American region, this disease is common among young women, and in Asia Pacific, emerging markets like India and China have a large population and a large patient pool.

The increasing health facilities in the region are driving the growth in the Asia Pacific market. The European market, including Germany, Italy, France, Russia, and Spain, is witnessing significant growth during the forecast period due to technological advancements, research and innovation in the medical field, and increasing awareness of chronic diseases. The presence of key players is the biggest factor in why North America is the leading segment. Increasing innovation in research and development activities is driving growth in the market.

Key Players

·         Pfizer Inc

·         Amag Pharmaceuticals

·         BioSante Pharmaceuticals

·         Shionogi and Co.

·         Patatin Technologies and Inc

·         Teva Pharmaceuticals Industries Ltd.

·         Apricus Biosciences Inc

·         Novartis

·         Johnson and Johnson

·         Other Players